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ABSTRACT
Human papillomavirus (HPV) is responsible for cervical cancer, and its role in 
head and neck carcinoma has been reported. No drug is approved for the treatment of 
HPV-related diseases but cidofovir (CDV) exhibits selective antiproliferative activity. 
In this study, we analyzed the effects of CDV-resistance (CDVR) in two HPV(+) 
(SiHaCDV and HeLaCDV) and one HPV(−) (HaCaTCDV) tumor cell lines. Quantification of CDV 
metabolites and analysis of the sensitivity profile to chemotherapeutics was performed. 
Transporters expression related to multidrug-resistance (MRP2, P-gp, BCRP)  
was also investigated.
Alterations of CDV metabolism in SiHaCDV and HeLaCDV, but not in HaCaTCDV, 
emerged via impairment of UMP/CMPK1 activity. Mutations (P64T and R134M) as 
well as down-regulation of UMP/CMPK1 expression were observed in SiHaCDV and 
HeLaCDV, respectively. Altered transporters expression in SiHaCDV and/or HeLaCDV, but 
not in HaCaTCDV, was also noted.
Taken together, these results indicate that CDVR in HPV(+) tumor cells is a 
multifactorial process.
INTRODUCTION
Cidofovir (CDV) is an acyclic nucleoside 
phosphonate (ANP) with broad spectrum anti-DNA 
virus activity [1]. Its intravenous form is approved 
for therapy of cytomegalovirus retinitis in AIDS 
patients [2]. CDV is also used off-label for treatment 
of several diseases associated with herpesviruses 
other than cytomegalovirus, comprising adeno-, pox-, 
polyoma-, and papillomaviruses [3–6]. Besides its 
well-characterized antiviral activity, CDV is active as 
an antitumor agent in several animal models, including 
human cervical carcinoma xenografts in athymic nude 
mice [7–10]. CDV inhibitory effect on tumor growth 
has been attributed to its recognition by cellular DNA 
polymerases and incorporation into genomic DNA 
causing DNA breaks and/or apoptosis induction [11]. 
The higher sensitivity of cervical carcinoma cells 
carrying the human papillomavirus (HPV) genome, 
i.e. SiHa [HPV16 (+)] and HeLa [HPV18 (+)] to CDV 
compared to primary human keratinocytes (PHKs) has 
been explained by the differential response of tumor 
cells and normal cells to DNA damage [12, 13].
The cytosolic UMP/CMP kinase 1, a key enzyme 
in the activation of antiviral and anticancer drugs, 
catalyzes the phosphorylation of (d)CMP analogues to 
their diphosphate forms [14–16]. 2′-deoxycytidine (dC) 
(i.e. lamivudine and emtricitabine) or 2′-deoxycytidine 
monophosphate (dCMP) (i.e. CDV) analogues require 
phosphorylation by UMP/CMPK1 [17]. The first and 
Oncotarget10387www.impactjournals.com/oncotarget
last phosphorylation steps of cytidine 2′-deoxynucleoside 
analogues are catalyzed, respectively, by deoxycytidine 
kinase (dCK) and nucleoside diphosphate kinase (NDPK) 
[17]. Similarly, the anticancer agents cytarabine (araC) 
and gemcitabine (dFdC) are activated by UMP/CMPK1 
following prior conversion to their 5′-monophosphate 
forms by dCK [18]. The mitochondrial form of UMP/
CMPK (i.e. UMP/CMPK2) possesses distinct substrate 
specificity since it recognizes dUMP and dCMP as best 
phosphate acceptors while the cytosolic form preferentially 
phosphorylates CMP and UMP [19]. Both enzymes are 
also able to phosphorylate nucleotide analogues such as the 
monophosphate forms of the anti-cancer agents araC-MP 
and dFdC-MP [15, 18–20].   
Failure to anticancer therapy is often due to 
drug-resistance because of emergence of mutations in 
the cellular target or in one of the activating enzymes, 
multidrug-resistance (MDR) events leading to efflux of the 
active metabolite, or activation of DNA repair pathways 
[21–23]. Several drug-resistance mechanisms for araC 
or dFdC were described, including i) deamination by 
cytidine deaminase which converts araC into the inactive 
metabolite araU [24, 25], ii) down-regulation of the 
equilibrative nucleoside transporter (hENT1), the major 
carrier for araC and dFdC uptake [26], iii) circumvention 
of dCK-dependent araC and dFdC phosphorylation by 
down-regulation of dCK expression or point mutations 
leading to weaker activation of araC and dFdC [27, 28].
Unlike araC and dFdC, CDV intracellular uptake 
occurs via fluid-phase endocytosis and is independent 
of hENT [29]. In primary kidney tubular cells, CDV 
uptake is mediated through the organic anion transporters 
OAT1, and to a lesser extent OAT3. CDV activation is 
independent from dCK since CDV bears a phosphonate 
moiety at its methoxyhydroxypropyl part, bypassing then 
the initial phosphorylation by a nucleoside kinase. Thus, 
CDV-resistance (CDVR) mechanisms are expected to be 
different from those described for cytosine nucleoside 
analogues. 
In this study, we investigated the impact of CDVR 
on UMP/CMPK1 and on nucleoside metabolism, in 
particular on CTP and UTP biosynthesis. Three cell lines 
[two HPV(+) (SiHa and HeLa) and one HPV(–) 
(HaCaT)] were selected in vitro for resistance to CDV 
and were denoted SiHaCDV, HeLaCDV and HaCaTCDV. 
The susceptibility of these cell lines to several 
chemotherapeutics was assessed, as well as, the emergence 
of multi-drug-resistance mechanisms through upregulation 
of specific transporters. The metabolism of CDV, and in 
particular its incorporation into genomic DNA, was also 
investigated in these CDVR cell lines.
RESULTS
Growth rate of CDVR cells and sensitivity to 
ANPs 
SiHaCDV and HeLaCDV had a significantly slower 
growth rate than parental cells [doubling time (DT) 
of 36 h versus 22 h and 24 h versus 21 h, respectively] 
(Figure S1). In contrast, cellular growth rates were not 
significantly different between HaCaTparental and HaCaTCDV 
cells (i.e. DT of 26 h and 23 h, respectively). 
To determine the sensitivity of parental and CDVR 
cells to CDV, CC50’s following 7 days of incubation in 
the presence of the drug were evaluated (Figure 1). The 
highest fold-resistance (FR) was found for SiHaCDV (> 133) 
while for HeLaCDV and HaCaTCDV, FR values were of > 18 
and > 49, respectively. 
The sensitivity of CDVR cells to several 
chemotherapeutics was also investigated (Figure 1). 
Five different levels of resistance/hypersensitivity were 
recognized when considering a statistical significant 
difference (p < 0.05) between compounds’ CC50 values 
for parental and CDVR cells together with FR values: high 
resistance (FR ≥ 10), moderate resistance (5 ≤ FR < 10), 
mild resistance (2.0 ≤ FR < 5), no resistance (0.4 < FR < 2.0) 
and hypersensitivity (0.4 ≥ FR). 
Regarding ANPs, SiHaCDV cells were found to be 
highly resistant to HPMP derivatives with a FR in the range 
of 10 to 133 and moderate resistant to PME derivatives 
(Figure 1). For HeLaCDV cells, high resistance was observed 
for cHPMPC, moderate resistance to HPMPO-DAPY, 
HPMP-5azaC, cHPMP-azaC and HPMPA, while 
mild resistance was found for 3-deaza-HPMPA, 
PMEA, PMEG and cPr-PMEDAP. HaCaTCDV was highly 
resistant to cHPMPC, HPMPA, cHPMPA, HPMP-5azaC, 
moderately resistant to cHPMP-5azaC and exhibited 
mild resistance to HPMPDAP and HPMPO-DAPY. 
Hypersensitivity to PMEDAP and PMEA was observed 
for HaCaTCDV .
Sensitivity of CDVR cells to distinct 
chemotherapeutic agents
The results for other chemotherapeutics, structurally 
unrelated to ANPs but possessing antiproliferative activity 
against several type of cancers, are shown in Figure 1. 
Moderate resistance was observed against fludarabine and 
mild resistance against cytarabine, camptothecin, SN-38 
and topotecan, while hypersensitivity was demonstrated to 
docetaxel when tested on the SiHaCDV. HeLaCDV was found 
to have high resistance to fludarabine and mild resistance 
to cytarabine, while hypersensitivity was found for 
daunorubicin. HaCaTCDV was shown to be hypersensitive 
to docetaxel, 5-fluorouracil and cytarabine.
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Microarray data highlighted some genes likely 
involved in hypersensitivity or resistance to different 
chemotherapeutics in CDVR cells. For some of the 
differentially expressed genes, in particular those coding 
for proteins involved in uptake/efflux of different 
chemotherapeutics, enzymes required for their activation 
or catabolism and their target proteins, protein level 
variations were indicated (Table 1).
In SiHaCDV, cross-resistance to camptothecin, SN-38 
and topotecan can be explained via up-regulation of 
efflux pump genes ABCG2 (BCRP) and/or ABCC2 
(MRP2) (Table 1), as demonstrated in previous studies 
with different malignant cells [30–32]. Down-regulation 
of influx transporters SLC22A6 (OAT1) and SLC29A1 
(ENT1), and decreased expression of phosphorylating 
enzymes (AK2 and CMPK1), may be responsible for 
Figure 1: Sensitivity of parental and CDVR SiHa, HeLa and HaCaT cells to different ANPs and other chemotherapeutics. 
Between parentheses are presented the fold resistance values for each compound.
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cross-resistance to fludarabine and cytarabine, 
respectively. 
In HeLaCDV, up-regulation of the DNA polymerase ɛ 
sub-unit 4 (POLE4) (a subunit responsible for activation 
of replication and repair) might explain cross-resistance 
to fludarabine (Table 1) because of increased excision of 
fludarabine incorporated into DNA [33]. Hypersensitivity 
to docetaxel, 5-FU and cytarabine in HaCaTCDV could 
be mediated through up-regulation of influx transporters 
(SLC29A2; ENT2) or proteins involved in drug catabolism 
such as CYP1B1 and CYP3A7.
Differential protein expression of MRP2, BCRP, 
P-gp and OAT1 transporters
The differential expression of several transporters 
involved in multidrug-resistance [i.e. MRP2 (ABCC2), 
P-gp/MDR1 (ABCB1), BCRP (ABCG2) and OAT1 
(SLC22A6)] was measured by Western blot. OAT1 was 
downregulated in SiHaCDV and HeLaCDV (2-fold) but not in 
HaCaTCDV (Figure 2A–2D). BCRP levels were increased in 
SiHaCDV but not in HeLaCDV and HaCaTCDV (Figure 2A–2D). 
MRP2 was only upregulated in SiHaCDV (Figure 2B–2D) 
while P-gp was not affected in any of the three CDVR cell 
lines (Figure 2C–2D).
The sensitivity of parental and CDVR cells to 
different MDR or P-gp inhibitors was then assessed 
(Figure S2). Zosuquidar and Tariquidar (P-gp inhibitors) 
as well as Reversan and MK-571 (MRP inhibitors) act as 
competitive inhibitors while verapamil and indomethacin 
are non-competitive inhibitors of MRP1. SiHaCDV showed 
hypersensitivity to reversan but not to MK-571. HeLaCDV 
displayed hypersensitivity to reversan and verapamil 
while HaCaTCDV showed hypersensitivity to tariquidar and 
indomethacin. 
Table 1: Genes that might be involved in resistance or hypersensitivity to antiproliferative drugs 
in SiHa (A), HeLa (B) and HaCaT (C)
A Docetaxel Fludarabine Cytarabine Camptothecin SN-38 Topotecan
SiHaCDV
Hypersensitivity
MAP2 (−1.30)
MAPT (−1.00)
Resistance
SLC29A1 
(−1.59)
Resistance
CMPK1 
(mutations)
(↓protein)
NT5E (+ 2.20)
Resistance
ABCC2 (+ 2.17)
(↑protein)
ABCG2 (+ 1.02)
(↑protein)
Resistance
ABCC2 (+ 2.17)
(↑protein)
ABCG2 (+ 1.02)
(↑protein)
Resistance
ABCG2 (+ 1.02)
(↑protein)
TOP2A (+ 1.02)
B Fludarabine Cytarabine Daunorubicin
HeLaCDV
Resistance
AK2 (−1.19)
POLE4 (+ 1.15)
Resistance
CMPK1 (−1.29)
(↓protein)
NT5E (+ 1.08)
Hypersensitivity
?
genes involved in DNA damage 
response
C Docetaxel 5-Fluorouracil Cytarabine
HaCaTCDV Hypersensitivity
TUBB2A (−1.01)
KIF1C (−1.24)
KIF3C (−1.27)
ABCC3 (−2.86)
CYP1B1 (−1.05)
CYP3A7 (−2.77)
Hypersensitivity
SLC29A2 (+ 1.47)
ABCC3 (−2.86)
Hypersensitivity
CMPK1 (−0.31)
(≈protein)
NT5E (−1.00)
Abbreviations: TUBB2A: tubulin beta 2A, MAP2: microtubule associated protein 2, MAPT: microtubule associated protein tau, 
KIF1C: kinesin like protein 1C, KIF3C: kinesin like protein 3C, CYP1B1: cytochrome P450 1B1, CYP3A7: cytochrome P450 
3A7, SLC29A1/A2: equilibrative nucleoside transporter 1/2, AK2: adenylate kinase 2, POLE4: DNA polymerase epsilon subunit 4, 
ABCG2: ATP binding cassette type G2, NT5E: ecto-5′-nucleotidase (CD73), CMPK1: UMP/CMP kinase 1, TOP2A: 
topoisomerase II A, ABCC2/3: ATP binding cassette type C2/C3. 
Note: Between parentheses are shown the fold change (logN FC) of the upregulated (+) and downregulated (–) genes. 
For resistance or hypersensitivity consideration, the cut-off was set to 2.5 (for resistance) and 0.4 (for hypersensitivity). 
↑, ↓ and ≈ symbolize, respectively, increase, decrease and unchanged level of protein expression as observed by Western blot. 
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We next evaluated CDV and HPMPA 
antiproliferative activities in presence of MDR or P-gp 
inhibitors to rule out differences in transport of purine 
and pyrimidine analogues (Figure S3). SiHaparental was less 
sensitive to CDV and HPMPA in presence of the MRP 
inhibitor MK-571. In HeLaCDV, the HPMPA CC50 value 
was lower in presence of 4 µg/ml of zosuquidar than 
without inhibitor. The other inhibitors did not revert the 
resistant phenotype. These data point to some alterations 
of MDR and/or P-gp transporters in SiHaCDV and HeLaCDV 
cells but not in HaCaTCDV.
Intracellular CDV metabolism 
The impact of drug-resistance acquisition on 
CDV metabolism was analyzed to detect alterations in 
CDV activation by cellular kinases. In SiHaCDV cells, 
reduced amounts of CDV, CDV monophosphate (CDVp), 
CDV diphosphate (CDVpp) (the active drug form) and 
CDVp-choline were measured compared to SiHaparental 
cells, but only the decrease in CDVp was statistically 
significant (Figure 3A). Interestingly, the incorporation 
of CDV into cellular DNA, measured after a drug-
exposure of 24 h, was reduced by 50% in SiHaCDV cells 
(p = 0.0002) (Figure 3D). A more pronounced decrease in 
CDV activation was observed in HeLaCDV cells (p < 0.05 for 
all four metabolites) (Figure 3B) and CDV incorporation 
into DNA was also reduced by 50% (p = 0.0006). 
In contrast, in HaCaTCDV cells, no significant differences 
with parental cells were measured for CDV metabolites 
while, for CDV incorporation into DNA, a decrease of 30% 
was observed (Figure 3C and 3D). Hence, each CDVR 
cell type exhibited a different pattern of CDV activation 
compared to parental counterpart. 
Levels of UMP/CMPK1 affect CTP and UTP 
synthesis 
After analyzing protein expression of several 
influx/efflux pumps in CDVR lines, we next measured 
the expression of UMP/CMPK1, the enzyme responsible 
for the first phosphorylation of CDV, in order to detect 
any possible impairment in the activation pathway of the 
drug. Parental SiHa and HeLa cells expressed 6-fold more 
UMP/CMPK1 protein levels than the corresponding CDVR 
cells (p < 0.05) (Figure 4A). In contrast, the difference 
in UMP/CMPK1 expression between HaCaTparental and 
HaCaTCDV was only of 1.4-fold (p = 0.3679) (Figure 4B). 
For mitochondrial UMP/CMPK2, the fold-change between 
parental and CDVR cells was not statistically significant 
for any of the three cell lines.
The effects of changes on UMP/CMPK1 expression 
on CTP and UTP synthesis were investigated. CDP levels 
were significantly higher in parental cells than in CDVR 
SiHa and HeLa cells (3.4 to 3.7 fold-change) while in 
HaCaT cells, this difference was only of 1.7 (Figure 4C). 
Figure 2: Differential expression of several ABC and SLC transporters. Western blot detection was performed to measure 
the levels of OAT1 and BCRP (A), MRP2 (B), and P-gp (C). Quantification of each band was done and standardized using actin as 
housekeeping gene (D).
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These results are in line with the lower levels of UMP/
CMPK1 in SiHaCDV and HeLaCDV cells but not in HaCaTCDV 
cells (Figure 4A–4B). In parallel, the levels of ATP and 
GTP were also measured in parental and CDVR cell lines 
(Figure S4). ATP levels were not significantly affected, 
in the tested conditions, in the different cell lines (Figure 
S4A) while, regarding GTP levels, a significant increased 
level was only measured in HaCaTCDV cells compared to 
the parental counterparts (Figure S4B).
Since UMP/CMPK1 activity is impaired in SiHa and 
Hela CDVR cells, uridine (Urd) and cytidine (Cyd) were 
added to the growth medium to restore CTP and UTP levels 
(Figure 4C). By supplementing the cells with 100 µM 
of Urd and Cyd, the difference in CDP levels between 
parental and CDVR cells was abolished. Interestingly, 
the 4-fold lower CTP levels in HeLaCDV cells than in 
parental cells was reverted by the addition of Urd/Cyd. In 
HeLaCDV cells, accumulation of CMP in the presence of 
Urd/Cyd was found while there was barely any difference 
in CMP level for HeLaparental cells with or without 
Urd/Cyd-supplements. Higher CTP levels in Urd/Cyd 
supplemented HaCaTCDV cells were observed than in the 
parental cells.
When radiolabeled Cyd and Urd were added to the 
cells and the levels of newly synthesized CTP and UTP 
were measured, CTP production was found to be higher in 
SiHaparental than in SiHaCDV (5-fold and 6-fold difference at 
6 h and 24 h post-treatment, respectively). For HaCaT and 
HeLa cells, the fold-changes in CTP production at 24 h 
were 1.9 and 0.9, respectively (Figure 4D). These data 
confirm a more pronounced difference in CTP production 
between SiHaCDV and SiHaparental cells than in the two other 
cell types. The UTP level variation seemed similar in the 
three cell types when measured at 24 h post-treatment 
(Figure 4D). 
Figure 3: Intracellular metabolism of CDV in parental and CDVR SiHa (A), HeLa (B) and HaCaT (C) cells. The 
intracellular levels of CDV, CDV monophosphate (CDVp), CDV diphosphate (CDVpp) and CDVp-choline have been measured using 
radiolabeled CDV. The mean values were calculated from at least three independent experiments. (D) The figure shows the incorporation of 
CDV into DNA for the three different cell types. The mean values have been calculated from two independent experiments.
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Molecular basis for resistance to CDV: 
identification of mutations in UMP/CMPK1
Two amino acid changes in the UMP/CMPK1 
of SiHaCDV cells were identified (Figure S5): P64T 
[in the mobile nucleotide monophosphate (NMP) binding 
domain] and R134M [in the LID domain] (Figure S6). 
A mixed population of wild-type or double-mutated UMP/
CMPK1, or two single mutated UMP/CMPK1 were found. 
Unlike SiHaCDV cells, no mutations in UMP/CMPK1 were 
detected in HeLaCDV and HaCaTCDV cells. No mutations in 
the UMP/CMPK2 gene were observed in the CDVR cells. 
We also genotyped the two HPV oncogenes, i.e. E6 and E7, 
in SiHaCDV and HeLaCDV cells, but no differences were 
observed between parental and CDVR. 
Enzymatic activity of recombinant UMP/CMPK1
To investigate the impact of the mutations 
identified in the UMP/CMPK1 of SiHaCDV cells, 
site-directed mutagenesis was performed on a plasmid 
containing the coding sequence for UMP/CMPK1 to 
produce mutant enzymes carrying the P64T, R134M or 
a combination of both amino acid changes. The enzyme 
Figure 4: (A) Western blot detection of UMP/CMPK1 and 2 in the parental and CDVR SiHa, HeLa and HaCaT cells. (B) Fold-change 
(parental/CDV) of UMP/CMPK1 and 2 gene expression based on relative quantification compare to actin gene expression. The bars 
indicate the statistical difference between SiHa, HeLa and HaCaT regarding UMP/CMPK1 downregulation. (C) Determination of CMP, 
CDP and CTP levels in parental and CDVR cells by HPLC. Fold change is indicated when the difference in level of nucleotides between the 
parental and the CDVR cell is statistically significant. (D) Ratio of parental over CDVR cells CTP and UTP levels determined by means of 
HPLC following radioactive cytidine and uridine supplementation. Radiolabeled nucleosides where added to the cell medium and CTP and 
UTP levels were measured after 6 h and 24 h. No CTP level was detected in HaCaTCDV cells, preventing the comparison to the parental cells.
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bearing the P64T substitution had impaired enzymatic 
activity compared to the wild-type protein. Using CMP 
and UMP as phosphate acceptor, the turn-over number 
kcat was, respectively, 0.31 s
−1 and 0.35 s-1 for the P64T 
mutant compared to, respectively, 125 s−1 and 188 s−1 for 
the wild-type enzyme (Table 2). The affinity (KM) for these 
substrates was also affected (KM values of 123 µM and 
250 µM for, respectively, CMP and UMP with the P64T 
UMP/CMPK1 mutant, instead of 20 µM and 100 µM 
with the wild-type enzyme). As a result, the catalytic 
efficiency (kcat/KM) for phosphorylation decreased in the 
range of 1,340- to 2,480-fold for the mutant P64T UMP/
CMPK1. The phosphorylation of dCMP and dUMP was 
also dramatically affected by the P64T substitution. dCMP 
was poorly phosphorylated by the P64T mutant, and 
dUMP was not metabolized at all under the experimental 
conditions used. The mutant P64T UMP/CMPK1 did not 
metabolize CDV and its 5-aza derivative (5azaCDV). 
The phosphorylation of these drugs by the wild-type 
enzyme was significantly slower than the rate seen for 
dCMP (kcat of 0.09 s
-1 and 0.47 s−1, for CDV and 5azaCDV, 
respectively versus 13.4 s−1). On the contrary, cytarabine 
monophosphate (araCMP) was phosphorylated by the 
mutant enzyme but with a dramatic decrease of the 
catalytic rate (kcat = 0.019 s
−1 and KM = 327 µM, instead of 
kcat = 130 s
−1 and KM = 315 for wild-type enzyme). 
The enzymes bearing the R134M amino acid 
change alone or in combination with the P64T, did not 
exhibit enzymatic activity with the natural substrates 
nor with CDV. The catalytic efficiencies obtained for the 
UMP/CMPK1, could be ranked from the best acceptor 
substrate to the weakest, as follows: CMP > UMP > 
araCMP > dCMP > dUMP > 5azaCDV > CDV for the 
wild-type enzyme, and CMP > UMP > araCMP ≥ dCMP 
for the mutant P64T enzyme. For the wild-type enzyme, 
the kinetic parameters obtained for the natural substrates 
were similar to those obtained in a previous study [15].
Impact of point mutations on UMP/CMPK1 
conformation and stability 
The effect of the two mutations on the stability of the 
UMP/CMPK1 protein was assessed by circular dichroism 
(CD). Far-UV CD spectra of wild-type UMP/CMPK1 
without ligand showed the characteristic shape of a 
α-helix-rich protein with minima at 208 nm and 222 nm 
and a maximum at 192 nm. The CD spectrum of mutant 
P64T UMP/CMPK1 showed significant changes in the 
minima 208 nm and 222 nm but the overall shape is 
indicating a strong a-helix content (Figure S7A). The 
effect of the amino acid change P64T is directly reflected 
on this α-helix environment since the minima at 208 nm 
and 222 nm appeared to be changed in comparison to the 
wild-type enzyme. The ratio [θ]222/[θ]208 evolved from 
1.006 to 0.809, indicating a change in the folding of the 
UMP/CMPK1 protein induced by the P64T amino acid 
change (θ, being the degree of ellipticity).
The stability of the wild-type and the three mutant 
UMP/CMPK1 proteins was also investigated by thermal 
denaturation at two different temperatures (i.e. 5°C and 
70°C). Figure S7B shows the De at these temperatures for 
the wild-type and the three UMP/CMPK1 mutants. The 
P64T mutant started at a less native state compared to the 
wild-type protein, but at 70°C, the enzyme was not totally 
unfolded. The R134M mutant was very sensitive to thermal 
denaturation and at high temperature, the denaturation 
state was comparable to that of the wild-type enzyme. The 
double mutant P64T + R134M was at an intermediate state 
between P64T and R134M (Figure S7B).
The R134M and P64T + R134M UMP/CMPK1 
mutants are more sensitive to heat denaturation, 
suggesting that the P64T substitution triggers important 
conformational changes, higher stability of the enzyme 
and markedly impaired activity regarding the natural 
substrates CMP, UMP, dCMP and dUMP. The mutation 
R134M totally inactivated the enzyme and, in addition, 
destabilized the secondary structure, leading to a 
temperature-sensitive protein.
Modeling studies of the P64T and R134M amino 
acid changes
Models of the human UMP/CMPK1 were built 
using as template the three-dimensional structure of the 
Dictyostelium discoideum UMP/CMPK in the closed 
conformation complexed with ADP and CMP (pdb code: 
2UKD). The cytosine base interacts via water-mediated 
hydrogen bonds and hydrophobic interactions with 
residues Ile-62, Val-63 and Asn-97 (Figure 5A). Pro-64 
is located next to Ile-62 and Val-63 and allows the 
positioning of these residues close to the cytosine moiety 
for the establishment of efficient interactions. The P64T 
substitution may modify the distance between Ile-62, 
Val-63 and CMP, and therefore reduce the intensity 
or abolish the interactions observed in the wild-type 
UMP/CMPK1 at this position (Figure 5B). The Arg-134 is 
located in the LID domain, a mobile domain that contains 
positively charged residues able to stabilize the phosphate 
of the ATP with the magnesium ion in the active site 
(Figure 5C). The amino acid change Arg-to-Met at position 
134 might dramatically decrease the number of polar 
interactions between the ATP and CMP molecules and 
the magnesium ion (Figure 5D). The typical interactions 
established between an arginine to bridge the phosphate of 
ATP and CMP for the enzymatic reaction are abolished in 
the presence of Met-134. As observed with the enzymatic 
studies, this mutation results in inactivation of the enzyme. 
The superposition between the open conformation of the 
human UMP/CMPK1 and the closed conformation of the 
Dictyostelium discoideum UMP/CMPK bound to CMP 
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clearly shows that the helix a4 undergoes an important 
movement while closing the active site (Figure 5E). 
The residue at position 64 is located at the hinge, triggering 
this important conformational change and, consequently, 
an amino acid change at this specific position might have 
an important effect on the catalytic activity of the enzyme. 
This hypothesis is consistent with the kinetic parameters 
obtained with the mutant P64T UMP/CMPK1 that 
exhibited slower rates of phosphorylation for the natural 
substrates CMP, UMP and dCMP.
DISCUSSION
Emergence of drug-resistance after long-term 
exposure to antiproliferative agents is frequently observed 
in anticancer therapy. In general, drug-resistance can 
be related to several mechanisms including decreased 
uptake of the drug, slower drug-activation and faster 
drug-excretion via efflux pump(s). Studies of cytarabine 
and gemcitabine resistance mechanism have played 
an important role in the characterization of pyrimidine 
metabolism in tumor cells, but up to now, no description 
of resistance has been done regarding UMP/CMPK1. This 
is the first report of mutations in the UMP/CMPK1 linked 
to drug-resistance.
In SiHaCDV cells, two mutations were identified in 
the CMPK1 gene leading to low levels of UMP/CMPK1 
protein. On the other hand, the reduced UMP/CMPK1 
protein level in HeLaCDV was linked to down-regulation 
of CMPK1 gene expression. In HaCaTCDV, no changes in 
UMP/CMPK1 protein content were detected. These results 
are in line with impairment of CDV metabolism in SiHaCDV 
and HeLaCDV but not in HaCaTCDV. These data highlight a 
different pattern of CDV metabolism in each CDVR cell 
lines and that reduction of UMP/CMPK1 protein level 
is not enough to explain CDVR, since HaCaTCDV cells 
exhibited CDVR despite no impairment of UMP/CMPK1.
Reduced levels of UMP/CMPK1 in SiHaCDV 
resulted in poor CDV activation as shown by a significant 
decrease in CDVp but not in CDVpp or CDVp-choline. 
The enzymatic UMP/CMPK1 assay demonstrated that 
both amino acid changes (i.e. P64T and R134M) abolished 
the capacity of the enzyme to efficiently phosphorylate 
CDV. However, we did detect intracellular CDVp and 
the subsequent metabolites CDVpp and CDVp-choline 
in SiHaCDV, suggesting that both wild-type and double 
mutant UMP/CMPK1s are expressed in these cells. The 
electropherograms of UMP/CMPK1 cDNA sequencing 
performed for SiHaCDV cells at passages 55 and 230 
showed a mixed population of wild-type and mutant 
cells (1:1 ratio) at both positions (Figure S5). Thus, 
it can be inferred that both mutations are present in 
one allele and the other allele encodes for a wild-type 
enzyme. Co-existence of a mixed population of cells, 
one expressing exclusively wild-type enzyme and the 
other one expressing only mutant UMP/CMPK1, appears 
to be highly improbable since SiHaparental cells have a 
faster growth rate and, hence, would overgrow SiHaCDV 
cells after several passages. Furthermore, the enzymatic 
study performed with mutant proteins showed that both 
P64T and R134M single mutations lead to impaired or 
non-functional enzymes while SiHaCDV cells were able to 
generate CTP from exogenous Cyd, UTP from added Urd, 
as well as CDVp and subsequent metabolites from CDV. 
Quantification of UMP/CMPK1 in SiHaCDV cells showed 
a dramatic decrease in the protein pool in comparison 
with parental cells. Protein stability assays showed that 
the P64T + R134M UMP/CMPK1 mutant is highly 
sensitive to temperature denaturation, and hence is an 
instable protein. Since the mutant enzyme is less stable, 
its intracellular half-life might be altered leading to faster 
degradation via the proteasome pathway. In conclusion, 
these data indicate that SiHaCDV cells most likely express 
both wild-type and mutant UMP/CMPK1.
The impact of altered UMP/CMPK1 expression on 
the activation of (d)C analogues might differ from cell to 
cell since it has been reported that modulation of UMP/
CMPK1 expression did not influence the activation of 
C and U analogues (dFdC, L-OddC and 5-FU) in RKO 
Table 2: Kinetic parameters (kcat, KM and kcat/KM) of the wild-type and the recombinant UMP/CMP 
kinases
kcat (s
−1) KM (µM) kcat/KM (M
−1s−1)
WT P64T R134M P64TR134M WT P64T R134M
P64T
R134M WT P64T R134M
P64T
R134M
CMP 125 ± 20 0.31 ± 0.04 n.d. n.d. 20 ± 5 123 ± 50 n.d. n.d. 6.25 × 106 2.52 × 103 n.d. n.d.
UMP 188 ± 10 0.35 ± 0.10 n.d. n.d. 100 ± 25 250 ± 25 n.d. n.d. 1.88 × 106 1.4 × 103 n.d. n.d.
dCMP 13.4 ± 4.2 0.036 ± 0.010 n.d. n.d. 110 ± 50 970 ± 220 n.d. n.d. 1.22 × 105 37 n.d. n.d.
dUMP 5.80 ± 1.6 n.d. n.d. n.d. 1034 ± 250 n.d. n.d. n.d. 5.61 × 103 n.d. n.d. n.d.
CDV 0.09 ± 0.04 n.d. n.d. n.d. 2300 ± 100 n.d. n.d. n.d. 40 n.d. n.d. n.d.
5azaCDV 0.47 ± 0.04 n.d. n.d. n.d. 2080 ± 250 n.d. n.d. n.d. 226 n.d. n.d. n.d.
araCMP 130 ± 5 0.019 ± 0.007 n.d. n.d. 315 ± 45 327 ± 30 n.d. n.d. 4.1 × 105 58 n.d. n.d.
Abbreviations: (n.d. not detected under our experimental conditions).
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Figure 5: Structure-function relationship analysis of the mutant UMP/CMPK1s. (A–B) Comparison of the NMP binding 
site of WT and P64T UMP/CMPK1s complexed to CMP (in blue). Mutation at position 64 is represented as a grey residue. Amino acids in 
interaction with the base of CMP are depicted in green; the black dashes represent the polar interactions between the active site and CMP. 
(C–D) ATP binding site of WT and R134M UMP/CMPK1s with position 134 colored in red. ADP, bound to the active site, is colored in 
blue. Magnesium ion is represented as green sphere. The surface representation of the active site shows the steric hindrance of amino acid 
change R134M on ADP binding. (E) Superposition of the UMP/CMPK1 in open (in purple) and closed (in grey) conformation, showing 
the important movement that the NMP binding domain undergoes upon CMP binding.
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cells but well that of 2FdC, araC and 5-FU in HeLa S3 
and HCT8 cells [34,35]. In our study, we observed that 
genes related to metabolism of nucleoside analogues, such 
as CMPK1 and SLC29A1, were differentially expressed 
in SiHaCDV compared to SiHaparental cells. However, these 
alterations were not linked to a drug-resistance phenotype 
such as gemcitabine-resistance. We cannot exclude that 
impairment of gemcitabine uptake and activation could be 
compensated by other transporters and enzymes (e.g. SLC 
29A2 and CMPK2). Furthermore, no data for the cell lines 
here studied have been published yet describing the uptake 
and activation of cytarabine, gemcitabine and CDV.
In HeLaCDV cells, the total CDV metabolism seemed 
to be affected since not only the amount of CDVp was 
reduced but also CDV, CDVpp and CDVp-choline 
pools. The impairment in the whole metabolism of CDV 
might imply a role for the uptake or efflux considering 
the reduced amounts of intracellular CDV and CDVpp, 
resulting in a decreased CDV incorporation into the 
genomic DNA.
In HaCaTCDV, no significant differences were 
observed regarding CDV metabolism and a small 
decrease in CDV incorporation into DNA was noted 
although a 58-fold resistance to CDV was found. Thus, 
other events may be responsible for CDVR in these cells, 
such as alterations in CDV-targeted cellular pathways. 
The microarray analysis performed on parental and CDVR 
HaCaT cells showed that DNA repair mechanism(s) might 
also be responsible for CDVR. The activation of these 
pathways might explain the resistance to CDV even if no 
significant impairment of the metabolism of this drug was 
registered. Furthermore, other cellular pathways (such 
as ‘Wnt/β-catenin signaling’, ‘ERK/MAPK signaling’, 
‘EGF signaling’, ‘NFkB signaling’ or ‘acute phase 
response signaling’) might have an effect on CDVR since 
several genes are differentially expressed in the HaCaTCDV 
compared to HaCaTparental.
The kinetic parameters obtained with the recombinant 
P64T UMP/CMPK1 enzyme with natural substrates 
indicated that the apparent affinity KM was not dramatically 
affected. The main reason for the impaired phosphorylation 
of natural substrates for this mutant enzyme was the rate 
of catalysis since the kcat values were 403-, 537- and 
372-fold slower for CMP, UMP and dCMP, respectively, 
than for the wild-type enzyme. The mobility of the NMP 
domain, induced by substrate binding to the active site, 
appears to play an important role in the catalysis reaction 
[36]. Substrate binding leads to displacement of 18 Å 
of E59 carbon α, a residue belonging to the NMP binding 
domain [37]. The P64 residue, located in the hinge, allows 
the NMP binding site main helices (α3–α4) to change 
conformation in order to stabilize the closed conformation 
of the enzyme. The amino acid change P64T may alter this 
mobility, affecting the rate of phosphorylation by UMP/
CMPK1 of any phosphate acceptor. 
Circular dichroism assays performed in thermal 
denaturing conditions demonstrated that the mutant P64T 
protein has a higher stability than the wild-type enzyme. 
By decreasing the mobility of the NMP domain, the P64T 
substitution may lead to a more compact protein. Even 
though the mutant enzyme acquires a higher stability, 
its enzymatic activity is dramatically impaired and CDV 
phosphorylation totally abolished.
The second affected position, R134, is located 
in the LID domain and is crucial for the activity of the 
UMP/CMPK1 enzyme since it interacts with ATP. 
The arginine to methionine change at the homologous 
position R132 in the human AMP kinase (that is 
structurally related to UMP/CMPK1) reduces the 
phosphorylation rate of AMP from 650 s-1 to 0.08 s-1 [38]. 
This conserved residue has an important role in the 
enzymatic activity of nucleoside monophosphate kinases, 
since it stabilizes the transition state for phosphate transfer 
between the two substrates. Circular dichroism analysis 
of the mutants bearing the R134M amino acid change 
revealed that the mutant protein has higher instability than 
the wild-type one, consistent with reduced protein levels. 
Several multidrug-resistance proteins have been 
shown to be upregulated in CDVR cells. Regarding ANPs, 
MRP4, -5, -7 and -8 were shown to confer resistance to 
adefovir (PMEA); MRP4 is associated with resistance to 
PMEG, cPr-PMEDAP and PMEDAP; and overexpression 
of MRP5 confers resistance to PMEDAP [39–43]. Today, 
none of these transporters has been studied in the context 
of CDVR, and we cannot exclude that upregulation of 
one of the MRPs might, in part, be responsible for CDVR 
in SiHaCDV, HeLaCDV and HaCaTCDV cells. For instance, 
MRP2 is upregulated in SiHaCDV, and CDV was shown 
to be both a substrate and an inhibitor of this transporter 
in primary tubular renal cells [44]. BCRP (ABCG2) 
was found upregulated in SiHaCDV while P-gp might be 
associated with HPMPAR in HeLaCDV, since zosuquidar, 
a known inhibitor of P-gp, decreased CC50 value for 
HPMPA (Figure S8), even if no upregulation of P-gp was 
seen in HeLaCDV. These results suggest that altered levels 
of BCRP, MRP2 and P-gp transporters might contribute to 
CDVR in SiHaCDV and/or HeLaCDV. 
On the other hand, CDV uptake has been described 
to be mediated by SLC22A6-encoded OAT1 and higher 
protein levels of OAT1 were found in SiHaparental and 
HeLaparental which may reduce CDV uptake. However, 
since fluid-phase endocytosis has been described as the 
major mechanism of CDV uptake, and the expression of 
SLC22A6 genes is predominantly observed in renal cells, 
the impact of altered OAT1 expression on intracellular 
CDV pools might be very limited [45].
The impaired activity of the UMP/CMPK1 enzyme 
in the SiHaCDV and HeLaCDV cells could explain, at least in 
part, their reduced growth rate. Since the R134M change 
destabilizes the structure of UMP/CMPK1 leading to a 
Oncotarget10397www.impactjournals.com/oncotarget
reduced amount of protein, the decrease in intracellular 
UTP and CTP pools in resistant cells may be responsible, 
at least in part, for their slower growth rate. Similarly, 
doubling times of HeLaparental and HeLaCDV cells were 
significant different suggesting an important role for UMP/
CMPK1 in cellular growth. In HaCaTCDV, no significant 
decrease in UMP/CMPK1 protein level and no significant 
difference in growth rate were noted, even if CDVR HaCaT 
cells appear to grow slightly faster than the parental 
counterpart. This might be the result of an increased GTP 
level in HaCaTCDV compared to HaCaTparental cells.
CDVR seems to be acquired through alterations 
of CDV metabolism (i.e. impairment of UMP/CMPK1 
activity) as well as MDR events (i.e. changes in expression 
of BCRP, MRP2 and OAT1) in SiHa and HeLa cells, 
indicating a multifactorial biochemical basis (Figure S8). 
On the other hand, in HaCaT cells, these factors were not 
found to be dramatically changed, suggesting that CDVR 
is mediated through an alternate mechanism that might 
involve genes linked to DNA damage response. In these 
cells, the levels of intracellular CDV metabolites were 
unaltered, further excluding the enzymes involved in CDV 
activation as responsible for the resistance phenotype. 
One may wonder whether the presence of a partial 
HPV genome and the constitutive expression of E6 and E7 
oncoproteins might influence drug-resistance acquisition, 
since both SiHaCDV and HeLaCDV, in contrast to HaCaTCDV 
cells, underwent impairment of CDV activation and 
incorporation as well as alterations in the expression of 
drug transporters. Mutations in UMP/CMPK1 responsible 
for CDV-resistance have been selected and characterized 
in HPV(+) tumor cells and, to our knowledge, it is the 
first time that this enzyme has been involved in resistance 
against an antiviral or an anticancer drug, in vitro or 
in vivo. Up to now, no CDVR has been observed in 
patients receiving CDV for HPV-associated diseases. 
Since UMP/CMPK1 is a key enzyme in the nucleoside 
salvage pathway, its activity cannot be substituted by 
another enzyme and therefore, the mutation-rate under 
drug-pressure might be very low. Hence, the high genetic 
barrier to CDVR may be considered as an asset for the 
use of this drug in cancer therapy. On the other hand, a 
low number of patients suffering from HPV-associated 
diseases (genital warts or laryngeal papillomatosis) shows 
an uncomplete response to CDV therapy. Genotyping 
of CMPK1 gene should be considered when CDV 
fails to clear HPV(+) cells in order to identify natural 
polymorphisms able to confer resistance to CDV.
The search for new drugs with anti-papillomavirus 
activity is urgently needed since, up to now, no 
chemotherapeutic agent has been brought to the market 
for the specific management of HPV-induced lesions. 
Although CDV has proven efficacious in the therapy 
of HPV-associated diseases, it has some limitations, 
the nephrotoxicity being the most encountered 
side-effect. Recent publications revealed some promising 
compounds such as the HIV-protease inhibitors lopinavir 
and nelfinavir, but further characterizations of their anti-
HPV activity are needed [46]. Also, inhibition of cellular 
pathways frequently altered in HPV-induced neoplasia, 
such as phosphatidylinositol-3-kinase signaling represent 
a suitable target for therapeutic intervention [47].
In conclusion, acquisition of resistance to CDV 
in tumor cell appears to be a multifactorial process and 
different mechanisms are involved in distinct cell lines. 
Importantly, we showed that alterations in UMP/CMPK1 
may contribute to CDV-resistance in some cell lines.
MATERIALS AND METHODS
Chemicals
The list of the ANPs and chemotherapeutics used in 
this study is provided in Tables S1 and Figure S9. The source 
of other chemical reagents was as follows: Uridine (Urd) 
and adenosine-5′-triphosphate (ATP) Calbiochem; cytidine 
(Cyd), Valeant Pharmaceuticals; cytidine-5′-monophosphate 
(CMP), uridine-5′-monophosphate (UMP), 2′-deoxycytidine-
5′-monophosphate (dCMP) and 2′-deoxyuridine-5′-
monophosphate (dUMP), Sigma-Aldrich; arabinocytidine-
5′-monophosphate (araCMP), [5-3H]-radiolabeled CDV 
and [5-3H]-uridine, Moravek Biochemicals; and [5-3H]-
radiolabeled cytidine, MP Biochemicals. 
Selection of CDVR cells and growth rate
SiHa [HPV16(+)] and HeLa [HPV18(+)] cells were 
obtained from ATCC (#HTB-35 and #CCL-2, respectively) 
(Manassas, USA). HaCaT [HPV(–)] cells were kindly 
provided by F. De Marco (Regina Elena Institute for Cancer 
Research, Rome, Italy). Cell cultures were maintained in 
Dulbecco’s modified Eagle’s medium supplemented with 
10% fetal calf serum. Selection of HeLaCDV and HaCaTCDV 
cells was performed as previously described for SiHaCDV 
cells [48]. The growth rate of CDVR cells compared to 
parental cells was evaluated as previously reported [48]. 
Doubling time (DT) was calculated with the formula: 
DT = (t2–t1)/(log2N2-log2N1), where t1 and t2 are the times 
at which the cells were counted, and N1 and N2 are the cells 
numbers at times t1 and t2.
Microarray experiments
Parental and CDVR cells were allowed to grow for 
72 h in medium without CDV. Total RNA of 1 × 106 cells 
was isolated with TRIzol reagent (Invitrogen) and further 
purified by RNeasy Mini Kit (Qiagen). RNA quality 
and quantity were assessed with a Bioanalyzer system 
(Agilent).
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Microarray data were generated as previously 
reported [12] and is deposited in the Gene Expression 
Omnibus (GEO, http://www.ncbi.nlm.nih.gov/projects/
geo) according to MIAME standards under accession 
number GSE39293: http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc = GSE39293. 
Bioinformatics analysis of differentially expressed 
(DE) genes was carried out with Ingenuity Pathways 
Analysis (IPA, Ingenuity® Systems) version 9 as 
previously reported [12]. 
Antiproliferative activity 
Inhibition of cell growth was determined following 
7 days of incubation with the assessed drug as previously 
described [49]. The antiproliferative effects were 
expressed as CC50 (50% cystostatic concentration), which 
is the concentration required to reduce cell growth by 50% 
relative to the number of cells in untreated control cell 
culture). Fold-resistance (FR) was calculated as the ratio 
of CC50 for CDV
R cells to CC50 for parental cells. 
Genotyping of UMP/CMPK1, UMP/CMPK2, 
HPV E6 and E7
Total mRNA from parental and CDVR cells was 
isolated with the Quickprep mRNA purification kit 
(Amersham Biosciences) and converted to cDNA with 
the first-strand cDNA synthesis kit (GE Healthcare). The 
entire cDNA from each selected gene was amplified by 
PCR using specific primers. The PCR products were 
purified using PCR product purification kit (Roche) 
and directly sequenced using a cycle-sequencing kit 
(Dyenamic dye terminator kit; Amersham Biosciences), 
specific primers targeting both strands of the specific gene, 
and a capillary DNA sequencing system (MegaBACE 500; 
Amersham Biosciences). The data were assembled and 
compared to the DNA sequences obtained from reference 
sequences using Vector NTI software (Invitrogen). The 
primers used for the genotyping of UMP/CMPK1 and 2, 
and HPV oncogenes E6 and E7 are listed in Table S2.
CDV metabolism 
[5-3H]-radiolabeled CDV (Moravek) was used 
to assess the metabolism and drug incorporation into 
cellular nucleic acid material in parental and CDVR cells. 
The assay was performed with 10 µM of CDV for 24 h, 
a protocol adapted to the one described previously [12]. 
All experiments were performed in duplicate.
Measurement of intracellular nucleotide levels 
To quantify the levels of CMP, CDP, CTP and UTP, 
semi-confluent parental and CDVR cells were grown 
in presence or absence of 100 µM of uridine (Urd) and 
cytidine (Cyd) for 72 h. Cells were trypsinized, collected 
by centrifugation, and subjected to cell lysis. To determine 
the nucleotide pools, the extracts were submitted to HPLC 
analysis on an anion exchange column [PartiSphere SAX 
column (4.3 mm × 125 mm), Whatman] followed by UV 
spectroscopy. In parallel, 5 µCi per flask of radioactive 
[5-3H] labeled Urd or Cyd, supplemented in the growth 
medium of the parental and CDVR cells were used to 
investigate UTP and CTP biosynthesis at 6 h and 24 h after 
addition of the nucleosides. 
Site-directed mutagenesis of UMP/CMPK1
The P64T, R134M and P64T/R134M changes 
were introduced in the pHL60-5 plasmid containing the 
UMP/CMPK1 gene with a three step protocol using the 
Quickchange Lightning Multi site-directed Mutagenesis kit 
(Agilent technologies®). Primer(s) (Table S2) containing 
the base change(s) were used to perform a PCR reaction 
in order to produce mutant strands prior to enzymatic 
digestion of the template with Dpn I. To amplify the 
mutated plasmids, XL10 gold ultracompetent cells were 
transformed. Sequencing of the full UMP/CMPK1 gene 
from the recombinant plasmid was performed on both 
strands to exclude any additional mutation.
Expression, purification and enzymatic activity 
measurement of recombinant UMP/CMPKs 
The wild-type and mutant UMP/CMPK1s were 
produced in Escherichia coli [strain BL21 Rosetta® 
(DE3) pLysS (Novagen)] as previously reported [14]. 
For protein purification, cells were broken by sonication 
and centrifuged for 30 min at 15,000 g and 4°C. The 
supernatant was added onto a column containing 
2 ml Ni-Nitrilotriacetic acid resin (Ni-NTA) (Qiagen, 
Benelux). Protein elution was performed using increasing 
concentrations of imidazol and fractions were collected 
and pooled for dialysis. Protein purity was analyzed 
by polyacrylamide gel electrophoresis (SDS-PAGE) 
in denaturing conditions. The catalytic activity of the 
recombinant wild-type and mutant forms of human 
UMP/CMPK1 was determined using a previously 
described method [16] based on ADP formation [50].
Circular dichroism
All circular dichroism (CD) spectra measurements 
were acquired using a JOBIN-YVON CD6 
spectropolarimeter as previously described [51]. CD 
measurements are reported as Dε (M–1.cm–1). The relative 
helix content was deduced according to Zhong and 
Johnson as the percent of helix = [Dε222nm × –10], where 
Dε222nm is the dichroic increment at 222 nm per residue 
[52]. Thermal denaturation curves of UMP/CMPK1s 
were obtained by monitoring Δe at 222 nm as a function 
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of temperature from 0°C to 70°C with 10°C temperature 
steps. Experiments were performed in triplicate.
Structural model for the amino acid changes in 
human UMP-CMPK1
The role of the amino acid changes identified in the 
human UMP-CMPK1 in SiHaCDV cells was investigated 
by building a model of the enzyme complexed to ADP and 
CMP based on the published three-dimensional structure 
of the Dictyostelium discoideum UMP-CMPK (pdb code: 
2UKD). Pymol Delano software was used to introduce the 
identified mutations and to visualize the generated models. 
A comparison of the open conformation of the human 
enzyme free of substrate (pdb code: 1TEV) and the closed 
conformation obtained by modeling was performed to 
predict the impact of the P64T mutation. All figures were 
generated using PyMol software.
Western blot analysis
UMP/CMPK1 and 2 were detected, respectively, 
using a mouse monoclonal antibody (ab77457) and a rabbit 
polyclonal antibody (ab103658) (Abcam, Cambridge, 
UK). Detection of the transporters P-glycoprotein 
(ab3083), MRP2 (ab3373), BCRP (ab130244) and OAT1 
(ab118346) was performed on total cell membrane extracts 
with Plasma membrane protein extraction kit (ab65400). 
The house-keeping gene actin was detected using a 
mouse monoclonal antibody (ab3280). Species-specific 
HRP-conjugated secondary antibodies (Dako, Denmark) 
were used, in combination with Supersignal West Pico or 
Femto Chemiluminescent substrate (Thermo Scientific, 
Rockford, IL, USA) 
Statistical analysis
Plotting and statistical analysis were performed 
using GraphPad software. The unpaired t-test was used 
to analyze several parameters between parental and 
CDVR cells (i.e. intracellular CDV metabolites, drug 
transporter protein levels, UMP/CMPK protein levels and 
drug-sensitivity). Comparison of CTP and UTP 
biosynthesis in parental and CDVR cells was carried out 
using the two-way analysis of variance test (two-way 
ANOVA). No correction for multiple testing was used 
due to the large number of statistical analyses performed. 
Data are presented as mean ± standard deviation (SD) and 
p < 0.05 was considered significant.
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